Close Menu

NEW YORK – Myriad Genetics said on Monday that its revenues for the three months ended Sept. 30 declined 22 percent year over year.

Total revenues for the period were $145.2 million, down from $186.3 million. It beat the consensus Wall Street estimate of $135.2 million.

The Salt Lake City-based firm is in the process of changing its financial year to match the calendar year and did not identify the quarter ending on Sept. 30.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.